

REMARKS

Applicant has amended the specification at page 1 to insert a revised sequence listing. The sequence listing is revised to recite all sequences in a 5' to 3' orientation. SEQ ID NOs 1, 14, 15, 17, 19, 24, 28, 30, 33, 36, 38, 41, 44, 51, and 53 are depicted in the corresponding figures in a 3' to 5' orientation. The sequences were inserted into the prior sequence listings and specification in the orientation shown in the figures; however, this reproduction of the sequences from the figures inadvertently resulted in the listing of these sequences in a 3' to 5' orientation. These sequences appear in the correct 5' to 3' orientation in the revised sequence listing provided herein. As the identity of each nucleotide at every position of these sequences remains the same with respect to the 5' or 3' end, no new matter is added.

The specification is further amended to correct the orientation of SEQ ID NO: 1 (at page 37, Table 1) as well as SEQ ID NOs 14, 15, 17, and 19 (at page 37, Table 2). Revised Tables 1 and 2 recite all sequences in a 5' to 3' orientation. As described *supra*, the sequences were inserted into the prior sequence listings and specification in the orientation shown in the corresponding figures; however, this reproduction of the sequences from the figures inadvertently resulted in the listing of these sequences in a 3' to 5' orientation. These sequences appear in the correct 5' to 3' orientation in the revised Tables. As the identity of each nucleotide at every position of these sequences remains the same with respect to the 5' or 3' end, no new matter is added.

The specification is further amended to correct sequence identifiers previously provided for the brief description of Figure 7B. This amendment is not substantive in nature.

Applicant has amended the drawings at Figure 7A to delete the term "3'" at the right of SEQ ID NO: 1 (also referred to as CF4), and, instead to recite the term "5'". The ordinarily skilled artisan would readily recognize the recitation of "3'" as a typographical error because the correct notation of "5'" is provided in Figure 7A, as filed in USSN 60/560,026, filed April 7, 2004, from which the instant application claims the priority benefit. Accordingly, no new matter is added.

The ordinarily skilled artisan would readily recognize that the recitation of SEQ ID NOs 1, 14, 15, 17, 19, 24, 28, 30, 33, 36, 38, 41, 44, 51, and 53 in the 3'-5' orientation was an inadvertent error. Moreover, because the orientation of these sequences was unambiguously

marked in the specification and drawings, as originally filed, the ordinarily skilled artisan could have readily derived the revised sequences recited in the 5' to 3' sequence. Accordingly, no new matter is added.

Upon entry of this amendment, claim 26 is pending. Claim 26 is amended to recite the nucleotides of SEQ ID NO: 1 in the proper 5' to 3' orientation as well as SEQ ID NO: 2.

For all of the foregoing reasons, no new matter is added.

CONCLUSION

The Commissioner is hereby authorized to charge any additional fees that may be due or credit any overpayment of same to Deposit Account No. 50-0311, Attorney Reference No. 24028-015 NATL. Should any questions or issues arise concerning this application, the Examiner is encouraged to contact the undersigned at the telephone number provided below.

Respectfully submitted,



Ingrid A. Beattie, Reg. No. 42,306
Attorney for Applicants
c/o MINTZ LEVIN
One Financial Center
Boston, Massachusetts 02111
Tel: (617) 542-6000
Fax: (617) 542-2241
Customer Number 30623

Dated: May 14, 2012